These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 6722834)

  • 1. Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer.
    Ingle JN; Ahmann DL; Gerstner JG; Green SJ; O'Connell MJ; Kvols LK
    Cancer Treat Rep; 1984 May; 68(5):803-4. PubMed ID: 6722834
    [No Abstract]   [Full Text] [Related]  

  • 2. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.
    Yap HY; Blumenschein GR; Keating MJ; Hortobagyi GN; Tashima CK; Loo TL
    Cancer Treat Rep; 1980; 64(2-3):279-83. PubMed ID: 7407762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer.
    Yap HY; Blumenschein GR; Hortobagyi GN; Buzdar AU; Schell FC; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):511-4. PubMed ID: 7180829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer.
    Tannock I; Erlichman C; Perrault D; Quirt I; King M
    Cancer Treat Rep; 1982 Sep; 66(9):1783-4. PubMed ID: 7116356
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of 5-day infusion of vinblastine in patients with advanced ovarian carcinoma.
    Shah MK; St Marie K; Catalano RB; Dierks K; Creech RH
    Cancer Treat Rep; 1985 Feb; 69(2):229-30. PubMed ID: 3882232
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.
    Kuebler JP; Hogan TF; Trump DL; Bryan GT
    Cancer Treat Rep; 1984 Jun; 68(6):925-6. PubMed ID: 6733709
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of divided-dose vinblastine in advanced malignancy.
    Young JA; Westlake D; Schnetzer GW; Keller AM; Sexauer JM; Newcomer LN
    Cancer Treat Rep; 1985 Jun; 69(6):607-10. PubMed ID: 4016767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
    Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.
    Yap HY; Blumenschein GR; Bodey GP; Hortobagyi GN; Buzdar AU; DiStefano A
    Cancer Treat Rep; 1981; 65(9-10):775-9. PubMed ID: 7273012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II trial with 5-day continuous infusion of vindesine in metastatic malignant melanoma.
    Mayol XF; Beltran J; Rubio-Bazan R; Rifa J; Costa RR; Lopez JJ
    Cancer Treat Rep; 1984 Sep; 68(9):1199-200. PubMed ID: 6444204
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
    Berruti A; Bitossi R; Bottini A; Bonardi S; Donadio M; Nigro C; Bertetto O; Danese S; Bertone E; Sarobba MG; Farris A; Katsaros D; Castiglione F; Volpe T; Lattuada S; Mancarella S; Dogliotti L
    Eur J Cancer; 2005 Jan; 41(2):249-55. PubMed ID: 15661550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
    Lu K; Yap HY; Loo TL
    Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinblastine and 6-thioguanine in the treatment of advanced breast cancer.
    Muss HB; White DR; Richards F; Copper MR; Stuart JJ; Spurr CL
    Cancer Treat Rep; 1978 Aug; 62(8):1233-5. PubMed ID: 688260
    [No Abstract]   [Full Text] [Related]  

  • 16. Vinorelbine as palliative therapy in advanced breast cancer.
    Gasco M; Gardin G; Repetto L; Campora E; Rosso R
    Anticancer Res; 1997; 17(2B):1431-3. PubMed ID: 9137510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of vindesine in patients with advanced breast cancer.
    Currie VE; Camacho F; Wittes R; Young C
    Cancer Treat Rep; 1980; 64(4-5):693-95. PubMed ID: 7427954
    [No Abstract]   [Full Text] [Related]  

  • 18. A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.
    Kouroussis C; Kalbakis K; Androulakis N; Agelaki S; Vamvakas L; Malas K; Souglakos J; Vardakis N; Georgoulias V
    Anticancer Res; 2004; 24(6):4217-21. PubMed ID: 15736475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-day continuous-infusion vinblastine in the treatment of breast cancer.
    Fraschini G; Yap HY; Hortobagyi GN; Buzdar A; Blumenschein G
    Cancer; 1985 Jul; 56(2):225-9. PubMed ID: 4005794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of divided-dose vinblastine in advanced breast cancer patients.
    Giaccone G; Bagatella M; Bertetto O; Donadio M; Calciati A
    Cancer Chemother Pharmacol; 1988; 21(1):65-7. PubMed ID: 3342466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.